Diamyd Medical AB

DMN

Company Profile

  • Business description

    Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

  • Contact

    Kungsgatan 29
    StockholmSE-111 56
    SWE

    T: +46 86610026

    https://www.diamyd.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 August 2026

    Employees

    33

Stocks News & Analysis

stocks

Perplexing buyback from overvalued ASX share

Earnings continue to grow but investor expectations are too high.
stocks

Most popular shares in SMSFs

With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks

Will China strong arm BHP into lower iron ore prices?

Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,208.509.00-0.10%
CAC 407,934.2616.260.21%
DAX 4024,387.93146.470.60%
Dow JONES (US)46,067.58587.981.29%
FTSE 1009,442.8766.53-0.70%
HKSE25,664.60224.88-0.87%
NASDAQ22,694.61490.182.21%
Nikkei 22546,915.971,664.47-3.43%
NZX 50 Index13,276.9974.93-0.56%
S&P 5006,654.72102.211.56%
S&P/ASX 2008,899.4010.30-0.12%
SSE Composite Index3,885.054.45-0.11%

Market Movers